Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 310.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 248,766 shares of the company's stock after purchasing an additional 188,163 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.10% of Maravai LifeSciences worth $1,356,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRVI. Lazard Asset Management LLC grew its stake in shares of Maravai LifeSciences by 9.7% in the fourth quarter. Lazard Asset Management LLC now owns 1,447,714 shares of the company's stock worth $7,890,000 after acquiring an additional 127,672 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Maravai LifeSciences in the fourth quarter worth $501,000. FORA Capital LLC acquired a new position in shares of Maravai LifeSciences in the fourth quarter worth $156,000. Bamco Inc. NY grew its stake in shares of Maravai LifeSciences by 3.8% in the fourth quarter. Bamco Inc. NY now owns 2,203,651 shares of the company's stock worth $12,010,000 after acquiring an additional 80,000 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in shares of Maravai LifeSciences in the fourth quarter worth $362,000. Hedge funds and other institutional investors own 50.25% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Craig Hallum dropped their price target on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Robert W. Baird lowered their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. UBS Group lowered their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a research note on Friday, March 21st. Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a research report on Friday, March 21st. Finally, Baird R W cut shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $6.64.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI traded up $0.18 on Thursday, reaching $2.39. The company's stock had a trading volume of 600,599 shares, compared to its average volume of 2,344,951. The stock has a market capitalization of $607.36 million, a P/E ratio of -1.46 and a beta of 0.19. Maravai LifeSciences Holdings, Inc. has a 52-week low of $1.67 and a 52-week high of $10.03. The stock's 50-day moving average is $2.06 and its two-hundred day moving average is $3.77. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to analysts' expectations of $44.01 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. Maravai LifeSciences's quarterly revenue was down 26.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.